Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24169816 | 0.84 | PBRM1 (0.39) | ALDH1A1KMT2AKDM4EHPGDCYP2C19 | |
| SCHEMBL17371768 | 0.82 | ALDH1A1 (0.38) | ALDH1A1KDM4EPIM3CYP2C19CYP1A2 | |
| SCHEMBL7547639 | 0.81 | KDM3B (0.46) | ALDH1A1KMT2ANOTUMKDM4EKDM3B | |
| SCHEMBL22679184 | 0.79 | BRD4 (0.41) | ALDH1A1KMT2AKDM4EHPGDCYP2C19 | |
| SCHEMBL4284402 | 0.79 | NR4A2 (0.44) | ALDH1A1KDM4EHPGDGAA | |
| SCHEMBL19812558 | 0.78 | KDM4E (0.41) | ALDH1A1KMT2ANOTUMKDM4EKDM3B | |
| SCHEMBL16863256 | 0.76 | KDM4E (0.41) | ALDH1A1KMT2ANOTUMKDM4EKDM3B | |
| SCHEMBL10823654 | 0.76 | PDE4A (0.38) | ALDH1A1KMT2ANOTUMKDM4EKDM3B | |
| SCHEMBL6937497 | 0.75 | ALDH1A1 (0.51) | ALDH1A1KMT2AKDM4EHPGDCYP2C19 | |
| SCHEMBL19243050 | 0.75 | NOTUM (0.40) | ALDH1A1KMT2ANOTUMKDM4EKDM3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61010565-A | — | — | None | — | — | JP | disclosed |
| US-12533354-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240376078-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20230044941-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230044941-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230031213-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| CN-114340633-A | Triaryl compounds for the treatment of PD-L1 disease | 凯莫森特里克斯股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3968996-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | ChemoCentryx, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| WO-1996017832-A1 | NOVEL GLUTAMATE RECEPTOR ANTAGONISTS: FUSED CYCLOALKYLQUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1996-06-13 | — | — | WO | disclosed |
| EP-0649443-A4 | OXAZOLONE DERIVED MATERIALS. | LEGOMER PARTNERS LP (US) | 1995-11-08 | — | — | EP | disclosed |
| WO-1995018186-A1 | MODULAR DESIGN AND SYNTHESIS OF AMINIMIDE CONTAINING MOLECULES | ARQULE PARTNERS, L.P. (US) | 1995-07-06 | — | — | WO | disclosed |
| WO-1995017903-A1 | MODULAR DESIGN AND SYNTHESIS OF OXAZOLONE-DERIVED MOLECULES | ARQULE PARTNERS, L.P. (US) | 1995-07-06 | — | — | WO | disclosed |
| EP-0649443-A1 | OXAZOLONE DERIVED MATERIALS | LEGOMER PARTNERS, L.P. (US) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994000509-A9 | OXAZOLONE DERIVED MATERIALS | — | 1994-03-17 | — | — | WO | disclosed |
| WO-1994001102-A1 | AMINIMIDE-CONTAINING MOLECULES AND MATERIALS AS MOLECULAR RECOGNITION AGENTS | LEGOMER PARTNERS, L.P. (US) | 1994-01-20 | — | — | WO | disclosed |
| WO-1994000509-A1 | OXAZOLONE DERIVED MATERIALS | LEGOMER PARTNERS, L.P. (US) | 1994-01-06 | — | — | WO | disclosed |
| JP-S6110565-A | PREPARATION OF URACIL-5-CARBOXYLIC ACID ESTER | TAKEDA CHEM IND LTD | 1986-01-18 | — | — | JP | disclosed |
| US-3953428-A | ANTIBACTERIAL | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533354-B2 | Triaryl compounds for treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | ALDH1A1 388/4885KMT2A 1574/4885NOTUM 4629/4885 |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | ALDH1A1 608/4885KMT2A 2186/4885NOTUM 4807/4885 |
| US-20230031213-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | ALDH1A1 301/4885KMT2A 2794/4885NOTUM 4082/4885 |
| US-20230044941-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CD274, PDCD1, PDCD1LG2 | ALDH1A1 380/4885KMT2A 568/4885NOTUM 4282/4885 |
| US-20240376078-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | ALDH1A1 301/4885KMT2A 2794/4885NOTUM 4082/4885 |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CD274, PDCD1, PDCD1LG2 | ALDH1A1 380/4885KMT2A 568/4885NOTUM 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.